Search Results
Your search for ,itS matches 8694 pages
Showing 601 - 650National Academy of Medicine Elects 100 New Members
The National Academy of Medicine (NAM) announced the election of 90 regular members and 10 international members during its annual meeting. Background Established originally as the Institute of Medicine in 1970 by the National Academy of Sciences, NAM addresses critical issues in health, science,...
My Melanoma Could Have Been Prevented
I have many of the risk factors for melanoma. I’m fair-skinned, blue-eyed, and have a family history of melanoma, as well as other skin cancers, so I’ve always been diligent about practicing sun safety and maintaining annual full-body skin exams to catch any suspicious moles or lesions that could...
HypoG-01 Trial: Reducing the Treatment Time for Breast Cancer Nodal Irradiation
A 3-week moderately hypofractionated radiotherapy regimen has been found to be noninferior to the 5-week fractionation when irradiating nodal areas in patients with breast cancer, according to data presented at the European Society for Medical Oncology (ESMO) Congress 2024.1 The 5-year results of...
Preoperative Chemotherapy and Perioperative Nivolumab in NSCLC
As reported in The Lancet Oncology by Provencio et al, analysis of a Spanish phase II trial (NADIM) showed good long-term outcomes with preoperative chemotherapy and perioperative nivolumab in patients with stage IIIA non-small cell lung cancer (NSCLC). Study Details In the multicenter trial, 46...
MRI May Help Prevent Unnecessary Surgery in Patients With Rectal Cancer
Magnetic resonance imaging (MRI) may help patients with rectal cancer avoid invasive surgery and its potentially lifelong side effects, according to a recent study published by Williams et al in Radiology. Background “After undergoing chemotherapy and radiation for rectal cancer, patients are...
Conversations on Cancer: Exploring Religious Literacy and Spirituality in Cancer Care
OCE Insights is an occasional department developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, the OCE’s Steven Clark Cunningham, MD, MLA, FACS, Clinical Reviewer on the Gastrointestinal Cancers Team, ...
Meeting the Long-Term Challenge of Achieving Equity in Global Cancer Care
Although significant progress has been made against cancer, especially in the United States, which has seen the overall death rate from cancer fall by 33% over the past 3 decades, translating into averting an estimated 3.8 million deaths from the disease,1 progress worldwide has not been as...
Shared Reflections on the 2024 ASCO Annual Meeting: From Networking to Mentorship and More, Part 2
In the October 10, 2024, issue of The ASCO Post, we shared some unique insights from several recipients of the international development and education award (IDEA). As oncologists and cancer researchers from diverse low- and middle-income countries, their experiences at the 2024 ASCO Annual Meeting ...
Raising Awareness of the Health Consequences of Alcohol Consumption During and After a Cancer Diagnosis
In 2023, the World Health Organization (WHO) declared that “no level of alcohol consumption is safe for our health.”1 The warning came decades after the International Agency for Research on Cancer classified alcohol as a Group 1 carcinogen, which is the highest risk group, and also includes...
AMA House of Delegates Adopts ASCO-Sponsored Resolutions on Interpretation of Stark Law and Prior Authorization Costs
On September 23, 2024, the U.S. House of Representatives passed the Seniors’ Access to Critical Medications Act of 2024 (H.R. 5526), which would make permanent a waiver put in place during the COVID-19 pandemic that allowed Medicare patients to receive medications dispensed by in-office pharmacies...
CARMEN-LC03: Tusamitamab Ravtansine vs Docetaxel in Previously Treated Advanced Nonsquamous NSCLC
The multicenter phase III CARMEN-LC03 trial did not meet its dual primary endpoints of progression-free and overall survival with the CEACAM5-directed antibody-drug conjugate tusamitamab ravtansine vs standard chemotherapy with docetaxel in previously treated patients with advanced nonsquamous...
Heart Failure and Cancer: New Insights Into Reciprocal Relationship
Investigators have highlighted a critical connection between heart failure and cancer, demonstrating how shared mechanisms may contribute to the incidence and progression of both diseases, according to a recent scientific statement published by Bloom et al in the Journal of Cardiac Failure....
Osimertinib Plus Savolitinib: Responses Reported in First-Line Treatment of MET-Aberrant, EGFR-Mutant NSCLC
The combination of the EGFR tyrosine kinase inhibitor osimertinib and the MET inhibitor savolitinib has demonstrated clinically meaningful improvements compared with osimertinib alone as a first-line treatment of patients with de novo MET-aberrant, EGFR-mutant advanced non–small cell lung cancer...
Accelerated Approval for Bladder Cancer Drug to Be Withdrawn After Negative Trial
On October 18, Gilead Sciences announced its plans to voluntarily withdraw the U.S. accelerated approval for sacituzumab govitecan-hziy (Trodelvy) for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing...
Advancing Diversity, Equity, and Inclusion Through a Challenging Policy Landscape
Among most members of the health-care and oncology workforces, the lofty goals of the organizational framework of diversity, equity, and inclusion (DEI) seem to be clear and indisputable: to promote the fair treatment and full participation of all people, particularly groups who have historically...
ADRIATIC Trial: Durvalumab Consolidation Extends Survival in Limited-Stage Small Cell Lung Cancer
Consolidation therapy with the PD-1 immune checkpoint inhibitor durvalumab is set to become the new global standard of care for patients with limited-stage small cell lung cancer (SCLC), according to groundbreaking data presented at the European Society for Medical Oncology (ESMO) Congress 2024.1...
Trial Updates in Stage III Melanoma Solidify the Neoadjuvant Use of Immunotherapy as the Current Standard of Care
Neoadjuvant therapy for patients with resectable stage III melanoma has recently emerged as a better approach than resection plus adjuvant therapy. At the European Society for Medical Oncology (ESMO) Congress 2024, updates of pivotal neoadjuvant studies demonstrated the long-standing benefit of...
New Directions in ALL, CML, and CLL Treatment
The Society of Hematologic Oncology (SOHO) 2024 Annual Meeting showcased several groundbreaking studies in the field of hematologic oncology, including key findings in childhood acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), and chronic lymphocytic leukemia (CLL). The ASCO...
Higher Dosage of Radioembolization With Y-90 Therapy May Improve Survival Rates and Facilitate Curative Treatment in Patients With Hepatocellular Carcinoma
Researchers found that a higher dosage of radioembolization treatment using yttrium (Y)-90 microspheres than previously recommended may benefit patients with hepatocellular carcinoma, according to a recent study published by Chen et al in Liver Cancer. The findings could be practice-changing....
Overall Survival Analysis Confirms Pembrolizumab Regimen as Standard of Care for Triple-Negative Breast Cancer
For women with early-stage triple-negative breast cancer, KEYNOTE-522 changed the treatment paradigm several years ago. Support for neoadjuvant use of the PD-1 inhibitor pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab, was bolstered by the positive overall survival analysis...
Global Disparities May Exist in Availability, Timeliness of New Cancer Drugs
Despite considerable progress in the discovery and development of new cancer drugs between 1990 and 2022, there may be disparities in both the availability and timeliness of these treatment options globally, particularly among lower-income countries, according to a recent study published by Li et...
One-Dose HPV Vaccination Approach May Help to Eliminate Cervical Cancer
Canadian vaccination programs may switch to a one-dose, gender-neutral human papillomavirus (HPV) vaccination approach to eliminate cervical cancer, according to a recent study published by Drolet et al in the Canadian Medical Association Journal. Background HPV is known to cause cervical cancer...
Exercise Linked to Fewer Falls in Older Adults With Cancer
A recent study suggests that for people older than age 65 who have cancer, physical activity may be key to reducing the chances of a dangerous fall. People with lung cancer, colorectal cancer, or prostate cancer, in particular, had a lower risk of falling when they talked with their doctor...
ACA’s Dependent Coverage Expansion May Have Benefited Young Adult Patients Diagnosed With Cancer
Investigators have uncovered that during the Patient Protection and Affordable Care Act’s (ACA) first decade, the survival rates of Dependent Coverage Expansion–eligible young adult patients with cancer may have improved, according to a recent study published by Roth et al in Cancer. The federal...
Shared Reflections on the 2024 ASCO Annual Meeting: From Networking to Mentorship and More
The ASCO Annual Meeting brings together oncologists, researchers, and health-care professionals to share the latest advancements in cancer care. The 2024 ASCO Annual Meeting (ASCO24) was particularly momentous for those of who received the international development and education award (IDEA). As...
Two U.S. Scientists Named Recipients of the 2024 Nobel Prize in Physiology or Medicine
The 2024 Nobel Prize in Physiology or Medicine has been awarded jointly to two U.S. scientists: Victor Ambros, PhD, and Gary Ruvkun, PhD, for the discovery of microRNA and its role in post-transcriptional gene regulation. The recipients were named in a news release issued by The Nobel Assembly at ...
ASHP Offers New Guidance for Managing IV Fluid Shortages
The American Society for Health-System Pharmacists (ASHP) and the University of Utah announced updated recommendations for managing intravenous fluid shortages and conserving supply after Hurricane Helene forced the closure of a critical manufacturing plant in North Carolina. The management and...
ASCO Updates Stage III NSCLC Guideline to Include Osimertinib in Wake of LAURA Trial Data
ASCO has issued a rapid update to its guideline on the management of stage III non–small cell lung cancer (NSCLC), based on the results of the phase III LAURA trial, which was presented at the 2024 ASCO Annual Meeting and published simultaneously in The New England Journal of Medicine.1,2 The...
PEACE-3: Enzalutamide Plus Radium-223 Significantly Improves Survival in Metastatic Castration-Resistant Prostate Cancer
Initial analysis from the PEACE-3 trial suggests that the addition of radium-223 dichloride to enzalutamide could offer a promising new first-line treatment option for patients with metastatic castration-resistant prostate cancer, according to data presented by lead study author, Silke Gillessen,...
LEAP-012: Combination of Therapies Extends Progression-Free Survival in Intermediate-Stage Hepatocellular Carcinoma
The combination of the VEGF tyrosine kinase inhibitor lenvatinib, the PD-1 inhibitor pembrolizumab, and transarterial chemoembolization (TACE) significantly improved progression-free survival in patients with intermediate-stage hepatocellular carcinoma (HCC) compared with TACE alone, according to...
AI Language Models May Generate Effective Physician's Letters
An artificial intelligence (AI) algorithm may be effective at writing physician’s letters, according to a recent study published by Heilmeyer et al in JMIR Medical Informatics. Background According to recent surveys, physicians may spend almost 3 hours per day on documentation activities. “The...
ChatGPT May Demonstrate Human-Level Assessment of Brain Tumor MRI Reports
In the field of radiology, where a correct diagnosis is critical to ensure proper patient care, large language models such as ChatGPT may improve accuracy or offer a second opinion in assessing brain tumor magnetic response imaging (MRI) reports, according to a recent study published by Mitsuyama...
Conversations on Cancer: Exploring Religious Literacy and Spirituality in Cancer Care
OCE Insights is an occasional department developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, the OCE’s Steven Clark Cunningham, MD, MLA, FACS, Clinical Reviewer on the Gastrointestinal Cancers Team, ...
Navigating Uncharted Waters in the Post-Chevron Sea Change
It is not often that the oncology community looks to the Supreme Court to forecast its future. In 2024, two decisions seemingly unrelated to health care were issued that are likely to have a monumental impact on oncology care delivery. The Court’s rulings—on June 28, Loper Bright Enterprises et ...
ACS Report: Despite Overall Decreases in Breast Cancer Mortality, Incidence Rising in Key Groups
The American Cancer Society (ACS) recently released Breast Cancer Statistics, 2024, the organization’s biennial update on breast cancer occurrence and trends in the United States. The new report finds breast cancer mortality rates overall have dropped by 44% since 1989, averting approximately...
Immunotherapy/Chemoradiotherapy for Patients With Limited-Stage Small Cell Lung Cancer
Findings of a multi-institutional phase III trial indicated that people with limited-stage small cell lung cancer may benefit from the addition of immunotherapy to chemoradiotherapy, but not if both treatments are given simultaneously, new research finds. The results suggest that the timing of when ...
Adding Durvalumab to Neoadjuvant Regimen Improves Pathologic Complete Response Rate in High-Risk Breast Cancer
Adding the immune checkpoint inhibitor durvalumab, with or without the monoclonal antibody oleclumab, to neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT) significantly improved pathologic complete response rates in patients with high-risk hormone receptor (HR)-positive breast ...
EMBER: Imlunestrant in Estrogen Receptor–Positive, HER2-Negative Advanced Breast Cancer
In the the phase IA/B dose-escalation and -expansion EMBER study reported in the Journal of Clinical Oncology by Jhaveri et al, the next-generation oral selective estrogen receptor degrader imlunestrant (alone and in combination with other targeted therapies) demonstrated a manageable safety...
Creating a Culture of Diversity, Equity, and Inclusion: Why It Matters Clinically and Ethically
The National Comprehensive Cancer Network (NCCN) has always prided itself on its commitment to evidence-based, expert consensus–driven recommendations for cancer care, with a special focus on breaking down the barriers that contribute to disparities in outcomes across all patients with cancer. With ...
Amivantamab-vmjw Plus Lazertinib Improves Long-Term Outcomes in First-Line Setting of EGFR-Mutant Advanced NSCLC
The combination of the EGFR-MET bispecific antibody amivantamab-vmjw and the EGFR tyrosine kinase inhibitor lazertinib continues to demonstrate superior efficacy compared with the kinase inhibitor osimertinib alone in the first-line treatment of EGFR-mutant advanced non–small cell lung cancer...
Black Patients With Triple-Negative Breast Cancer May Be Less Likely to Receive Immunotherapy Compared With White Patients
Black patients with triple-negative breast cancer may receive immunotherapy at lower rates than White patients, according to new findings presented by Freeman et al at the 2024 American Association for Cancer Research (AACR) Conference on the Science of Cancer Health Disparities in Racial/Ethnic...
Phase III CABINET Trial: Cabozantinib in Advanced Neuroendocrine Tumors
Cabozantinib may be effective at improving progression-free survival in patients with previously treated neuroendocrine tumors, according to recent findings presented by Chan et al at the European Society for Medical Oncology (ESMO) Congress 2024 (Abstract 1141O) and simultaneously published in The ...
ASCO Issues First Guideline Specific to Locally Advanced Rectal Cancer
ASCO has released its first clinical practice guideline focused specifically on the management of locally advanced rectal cancer.1 “Rectal cancer, and especially locally advanced rectal cancer, is a complex disease that requires individualized approaches using multimodality therapies to have the...
Optimizing the Use of Multicancer Early Detection Tests
Multicancer early detection (MCED) tests are beginning to enter clinical practice, but how useful will they be? “This is an exciting field, with many competing technologies. MCED assays will be coming across your desk in the near future if they haven’t already. But they are not a panacea. They are ...
Breast and Ovarian Cancers May Be Linked to Thousands of RAD51C Gene Variants
Researchers have identified thousands of genetic changes in a gene that may increase the risk of developing breast and ovarian cancers, according to a recent study published by Olvera-León et al in Cell. The findings may pave the way for better risk assessment and more personalized care. ...
The Formative Years of Medical Oncology in the United States: A Rough and Tumble Road, Part 2
Medical oncology had a turbulent beginning, as we explained in part 1 of this commentary published in the September 25, 2024, issue of The ASCO Post. And although no other specialty we know of struggled as much, with perseverance and time, it had become a stable specialty of internal medicine by...
The Formative Years of Medical Oncology in the United States: A Rough and Tumble Road, Part 1
Medical oncology had a turbulent beginning. No other specialty we know of struggled as much. But by 1980, it had become a stable specialty of internal medicine and was off and running—with the major problem of how to marshal available resources to freely test the myriad opportunities presented by ...
Addition of Palliative Radiotherapy to Best Supportive Care in Painful Hepatic Cancer
As reported in The Lancet Oncology by Laura A. Dawson, MD, of the University Health Network–Princess Margaret Cancer Centre, University of Toronto, and colleagues, the Canadian phase III CCRG HE1 trial showed that the addition of a single fraction of palliative radiotherapy to best supportive care...
NURE-Combo: First Results for a Perioperative Chemoimmunotherapy Approach in Muscle-Invasive Bladder Cancer
Based on the first results of the single-center phase II NURE-Combo trial, which were reported in the Journal of Clinical Oncology (JCO) by Mercinelli et al, the combination of neoadjuvant nivolumab plus nab-paclitaxel followed by postsurgical adjuvant nivolumab appeared to be safe and active in...
Retifanlimab Plus Chemotherapy May Extend Progression-Free Survival in Patients With Squamous Cell Anal Carcinoma
Retifanlimab plus platinum-based chemotherapy may benefit patients with squamous cell anal carcinoma, according to new findings presented by Rao et al at a presidential symposium at the European Society for Medical Oncology (ESMO) Congress 2024 (Abstract LBA2). Background The incidence of squamous...
